Patents by Inventor Jay Hess

Jay Hess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS TO REDUCE COMBUSTION TIME AND TEMPERATURE IN AN ENGINE
    Publication number: 20240110527
    Abstract: Methods and apparatuses are provided to reduce combustion time and/or combustion temperature in an internal combustion engine. In an exemplary embodiment, intake air and oxygen-rich gas are introduced upstream of a turbofan, wherein the amount of oxygen rich gas is controlled in proportion to the engine speed.
    Type: Application
    Filed: December 13, 2023
    Publication date: April 4, 2024
    Inventors: Hugh JONSON, Peter RIESSELMAN, Ron BINGEL, Jay MORROW, Fred HESS, Robb ROBEL
  • Compositions and methods relating to hindering DOT1L recruitment by MLL-fusion proteins
    Patent number: 9862746
    Abstract: The present invention relates to MLL fusion proteins (e.g., AF9 and ENL), which activate target genes in part via recruitment of histone methyltransferase DOT1L. In particular, the present invention provides the AF9/ENL binding site in DOT1L and agents that block the protein-protein interactions between AF9/ENL and DOT1L, therefore inhibiting the activity of DOT1L, and inhibiting MLL-fusion protein associated leukemia.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: January 9, 2018
    Assignee: The Regents of the University of Michigan
    Inventors: Zaneta Nikolovska-Coleska, Chenxi Shen, Jay Hess
  • Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
    Patent number: 9505781
    Abstract: The present disclosure relates generally to thienopyrimidine and thienopyridine compounds and methods of use thereof. In particular embodiments, the present disclosure provides compositions comprising thienopyrimidine and thienopyridine compounds of Formula 4b: and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: November 29, 2016
    Assignee: The Regents of the University of Michigan
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jay Hess, Duxin Sun, Xiaoqin Li
  • COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20160046647
    Abstract: The present invention relates generally to thienopyrimidine and thienopyridine class compounds and methods of use thereof. In particular embodiments, the present invention provides compositions comprising thienopyrimidine and thienopyridine class compounds and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins (e.g., for the treatment of leukemia, solid cancers and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin).
    Type: Application
    Filed: March 10, 2014
    Publication date: February 18, 2016
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jay Hess, Duxin Sun, Xiaoqin Li
  • COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA
    Publication number: 20160045504
    Abstract: The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion oncoproteins, and well as systems and methods to screen for such compositions.
    Type: Application
    Filed: March 23, 2015
    Publication date: February 18, 2016
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Jay Hess
  • COMPOSITIONS AND METHODS RELATING TO HINDERING DOT1L RECRUITMENT BY MLL-FUSION PROTEINS
    Publication number: 20150368300
    Abstract: The present invention relates to MLL fusion proteins (e.g., AF9 and ENL), which activate target genes in part via recruitment of histone methyltransferase DOT1L. In particular, the present invention provides the AF9/ENL binding site in DOT1L and agents that block the protein-protein interactions between AF9/ENL and DOT1L, therefore inhibiting the activity of DOT1L, and inhibiting MLL-fusion protein associated leukemia.
    Type: Application
    Filed: February 14, 2014
    Publication date: December 24, 2015
    Inventors: Zaneta Nikolovska-Coleska, Chenxi Shen, Jay Hess
  • Compositions and methods for treatment of leukemia
    Patent number: 8993552
    Abstract: The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion oncoproteins, and well as systems and methods to screen for such compositions.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: March 31, 2015
    Assignees: The Regents of The University of Michigan, University of Virginia Patent Foundation
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Jay Hess
  • COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA
    Publication number: 20110065690
    Abstract: The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion oncoproteins, and well as systems and methods to screen for such compositions.
    Type: Application
    Filed: September 3, 2010
    Publication date: March 17, 2011
    Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Jay Hess